ישראל - עברית - Ministry of Health

sanofi israel ltd - caplacizumab - אבקה וממס להכנת תמיסה להזרקה - caplacizumab 10 mg/vial - caplacizumab

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - bevacizumab - תרכיז להכנת תמיסה לאינפוזיה - bevacizumab 25 mg/ml - bevacizumab - bevacizumab - avastin in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of patients with metastatic carcinoma of the colon or rectum.avastin in addition to platinum - based chemotherapy is indicated for first - line treatment of patients with unresectable advanced metastatic or recurrent non- small cell lung cancer other than predominantly squamous cell histology. avastin in combination with interferon alfa-2a is indicated for first line treatment of patients with advanced and /or metastatic renal cell cancer. avastin in combination with paclitaxel is indicated for first-line treatment of patients with metastatic breast cancer.avastin as asingle agent, is indicated for the treatment of glioblastoma in patients with progressive disease following prior therapy.avastin, in combination with carboplatin and paclitaxel, is indicated for the front-line treatment of advanced (figo stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are at hig

ישראל - עברית - Ministry of Health

medison pharma ltd - natalizumab - תרכיז להכנת תמיסה לאינפוזיה - natalizumab 300 mg / 15 ml - natalizumab - natalizumab - tysabri is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis . to delay the accumulation of physical disability and reduce the frequency of clinical exacerbations. the safety and efficacy of tysabri beyond two years are unknown. because tysabri increases the risk of progressive multifocal leukoencephalopathy (pml), an opportunistic viral infection of the brain that usually leads to death or severe disability. tysabri is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, alternate multiple sclerosis therapies. safety and efficacy in patients with chronic progressive multiple sclerosis have not been studied.

ישראל - עברית - Ministry of Health

novartis israel ltd - canakinumab - אבקה להכנת תמיסה לזריקה - canakinumab 150 mg / 1 ml - canakinumab - canakinumab - cryopyrin - associated periodic syndromes (caps) in adults, adolescents and children aged 2 years and older with body weight above 7.5 kg, including : - mucle - wells syndrome (mws), - neonatal-onset multisystem inflammatory disease (nomid) / chronic infantile neurological, cutaneous, articular syndrome (cinca), - severe forms of familial cold autoinflammatory syndrome (fcas) / familial cold urticaria (fcu) presenting with signs and symptoms beyond cold-induced urticarial skin rash.gouty arthritis:ilaris is indicated for the symptomatic treatment of adults patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (nsaids) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.

ישראל - עברית - Ministry of Health

novartis israel ltd - canakinumab - תמיסה להזרקה - canakinumab 150 mg / 1 ml - canakinumab

ישראל - עברית - Ministry of Health

amgen europe b.v. - bevacizumab - תרכיז להכנת תמיסה לאינפוזיה - bevacizumab 25 mg / 1 ml - bevacizumab

ישראל - עברית - Ministry of Health

astrazeneca (israel) ltd - palivizumab - תמיסה להזרקה - palivizumab 100 mg/ml - palivizumab

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - bevacizumab - תרכיז להכנת תמיסה לאינפוזיה - bevacizumab 25 mg / 1 ml - bevacizumab

ישראל - עברית - Ministry of Health

kamada ltd, israel - bevacizumab - תרכיז להכנת תמיסה לאינפוזיה - bevacizumab 25 mg/ml - bevacizumab

ישראל - עברית - Ministry of Health

abbvie biopharmaceuticals ltd, israel - palivizumab 100 mg - powder for solution for injection - palivizumab - is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv). safety and efficacy were established in infants with bronchopulmonary dysplasia (bpd) and in infants with a history of prematurity (35 weeks gestational age) and in children less then 2 years of age,with haemodynamically significant congenital heart disease.